Status regarding Novo Nordisk's holding of its own shares (31 December 2013) Bagsværd, Denmark, 2 January 2014 - In continuation of the company's announcements dated 31 January 2013 and 31 October 2013 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 31 December 2013 owned 102,852,025 of its own B shares of DKK 0.20, corresponding to a total nominal value of DKK 20,570,405 or 3.7% of the total share capital.

In the fourth quarter of 2013 a total of 15,327,405 B shares of DKK 0.20 were repurchased, and 1,940,620 B shares of DKK 0.20 were disposed of to employees in connection with employee incentive programmes.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B

shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge

Ken Inchausti (US)

+45 4442 3450

+1 609 514 8316

amhg@novonordisk.com kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen

+45 3079 4303

krop@novonordisk.com

Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen

Jannick Lindegaard (US)

+45 3079 0604

+45 3075 3479

+45 3079 6376

+1 609 235 8567

fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet: www.novonordisk.com CVR no:

24 25 67 90

Company announcement No 1 / 2014

distributed by